CPRX · As filed with the SEC
Catalyst Pharmaceuticals balance sheet, by quarter
The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | 755,859,000 | 709,171,000 | 689,892,000 | 652,800,000 | 580,656,000 | 517,553,000 | 442,331,000 | 375,693,000 |
| Accounts receivable, net | 130,834,000 | 126,477,000 | 106,409,000 | 65,863,000 | 71,265,000 | 65,476,000 | 58,266,000 | 57,172,000 |
| Inventory | 34,930,000 | 37,166,000 | 28,029,000 | 18,650,000 | 19,778,000 | 19,541,000 | 20,017,000 | 18,014,000 |
| Prepaid expenses and other current assets | 18,767,000 | 21,216,000 | 28,123,000 | 21,426,000 | 14,019,000 | 21,039,000 | 18,384,000 | 23,550,000 |
| Total current assets | 940,390,000 | 894,030,000 | 852,453,000 | 758,739,000 | 685,718,000 | 623,609,000 | 538,998,000 | 474,429,000 |
| Operating lease right-of-use asset, net | 1,858,000 | 1,935,000 | 2,010,000 | 2,084,000 | 2,158,000 | 2,230,000 | 2,301,000 | 2,371,000 |
| Property and equipment, net | 994,000 | 1,037,000 | 1,077,000 | 1,149,000 | 1,239,000 | 1,354,000 | 1,380,000 | 1,227,000 |
| License and acquired intangibles, net | 121,971,000 | 131,674,000 | 128,639,000 | 137,983,000 | 147,327,000 | 156,672,000 | 166,016,000 | 175,361,000 |
| Deferred tax assets, net | 55,111,000 | 52,767,000 | 48,256,000 | 50,704,000 | 48,222,000 | 45,982,000 | 48,473,000 | 39,889,000 |
| Investment in equity securities | 27,286,000 | 22,536,000 | 19,167,000 | 21,256,000 | 24,208,000 | 21,564,000 | 14,842,000 | 13,083,000 |
| Total assets | 1,147,610,000 | 1,103,979,000 | 1,051,602,000 | 971,915,000 | 908,872,000 | 851,411,000 | 772,010,000 | 706,360,000 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | 7,151,000 | 11,202,000 | 9,096,000 | 5,528,000 | 11,197,000 | 16,593,000 | 11,563,000 | 7,116,000 |
| Accrued expenses and other liabilities | 125,247,000 | 135,950,000 | 119,639,000 | 107,479,000 | 100,452,000 | 104,085,000 | 93,832,000 | 85,202,000 |
| Total current liabilities | 132,398,000 | 147,152,000 | 128,735,000 | 113,007,000 | 111,649,000 | 120,678,000 | 105,395,000 | 92,318,000 |
| Operating lease liability, net of current portion | 2,235,000 | 2,350,000 | 2,461,000 | 2,572,000 | 2,681,000 | 2,786,000 | 2,889,000 | 2,991,000 |
| Other non-current liabilities | 280,000 | 209,000 | 161,000 | 309,000 | 259,000 | 315,000 | 2,785,000 | 2,396,000 |
| Total liabilities | 134,913,000 | 149,711,000 | 131,357,000 | 115,888,000 | 114,589,000 | 123,779,000 | 111,069,000 | 97,705,000 |
| Stockholders' equity: | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at March 31, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value, 200,000,000 shares authorized; 122,181,308 shares and 122,513,621 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 122,000 | 123,000 | 123,000 | 122,000 | 122,000 | 121,000 | 119,000 | 119,000 |
| Additional paid-in capital | 489,218,000 | 479,957,000 | 473,333,000 | 461,868,000 | 452,280,000 | 442,286,000 | 431,597,000 | 423,195,000 |
| Retained earnings | 523,349,000 | 474,188,000 | 446,789,000 | 394,006,000 | 341,898,000 | 285,161,000 | 229,225,000 | 185,341,000 |
| Accumulated other comprehensive income (loss) (Note 4) | 8,000 | 0 | 0 | 31,000 | (17,000) | 64,000 | 0 | 0 |
| Total stockholders' equity | 1,012,697,000 | 954,268,000 | 920,245,000 | 856,027,000 | 794,283,000 | 727,632,000 | 660,941,000 | 608,655,000 |
| Total liabilities and stockholders' equity | 1,147,610,000 | 1,103,979,000 | 1,051,602,000 | 971,915,000 | 908,872,000 | 851,411,000 | 772,010,000 | 706,360,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.